Literature DB >> 18321818

Conservative management of patients with early endometrial carcinoma: a systematic review.

Luis Chiva de Agustín1, Fernando Lapuente Sastre, Virginia Corraliza Galán, Luis Granados Galainena, Antonio González Martín, Lucía González Cortijo, Natalia Carballo González.   

Abstract

OBJECTIVE: To know the characteristics of endometrial adenocarcinoma in young patients and to review the published experience in patients with endometrial adenocarcinoma that were conservatively managed with hormonal therapy to spare their fertility.
METHODS: We carried out a search in the Survey conducted by the Section of Oncologic Gynecology of SEGO (Spanish Society of Gynecologists) to identify the characteristics of young patients with endometrial adenocarcinoma. In addition we searched MEDLINE and other databases for English-language articles describing patients with endometrial adenocarcinoma who were treated with hormonal therapy. The search included articles published between January 1966 and January 2007.
RESULTS: Endometrial carcinoma in patients under 45 years old is an unusual condition that shows a more favourable pattern than in older patients. One hundred and thirty-three patients were found in the search. The average duration of hormonal therapy was approximately six months. The average response time was 12 weeks; 76% of patients treated with hormonal therapy had a complete response and the other 24% never responded to treatment. Of those who initially responded, 66% percent did not show recurrence of disease. The other 34% had a relapse. There have been 4 published deaths of conservatively managed patients.
CONCLUSION: A conservative approach in these patients can offer reasonable oncological security and the opportunity of fulfilling their maternal desires in selected cases. However, consideration should be taken regarding the potential adverse outcomes that have been recently published in the literature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321818     DOI: 10.1007/s12094-008-0173-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  65 in total

1.  Primary hormonal treatment for early endometrial carcinoma.

Authors:  J Sardi; J P Anchezar Henry; G Paniceres; N Gomez Rueda; S Vighi
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

Review 2.  Hormonal treatment of endometrial cancer.

Authors:  G Emons; W Heyl
Journal:  J Cancer Res Clin Oncol       Date:  2000-11       Impact factor: 4.553

3.  Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium.

Authors:  C E Ehrlich; P C Young; F B Stehman; G P Sutton; W M Alford
Journal:  Am J Obstet Gynecol       Date:  1988-04       Impact factor: 8.661

4.  Pregnancy following hormonal therapy for adenocarcinoma of the endometrium.

Authors:  R T O'Neill
Journal:  Am J Obstet Gynecol       Date:  1970-09-15       Impact factor: 8.661

5.  Fertility-preserving treatment in young patients with endometrial adenocarcinoma.

Authors:  Chen-Bin Wang; Chin-Jung Wang; Huei-Jean Huang; Swei Hsueh; Hung-Hsueh Chou; Yung-Kuei Soong; Chyong-Huey Lai
Journal:  Cancer       Date:  2002-04-15       Impact factor: 6.860

6.  Successful in vitro fertilization pregnancy after conservative management of endometrial cancer.

Authors:  A B Pinto; M Gopal; T J Herzog; J D Pfeifer; D B Williams
Journal:  Fertil Steril       Date:  2001-10       Impact factor: 7.329

7.  Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.

Authors:  Shih-Yin Huang; Shih-Ming Jung; Koon-Kwan Ng; Yu-Chen Chang; Chyong-Huey Lai
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

8.  Profile of women 45 years of age and younger with endometrial cancer.

Authors:  E R Evans-Metcalf; S E Brooks; F R Reale; S P Baker
Journal:  Obstet Gynecol       Date:  1998-03       Impact factor: 7.661

9.  Characteristics and outcome of endometrial carcinoma patients age 45 years and younger.

Authors:  B N Tran; P P Connell; S Waggoner; J Rotmensch; A J Mundt
Journal:  Am J Clin Oncol       Date:  2000-10       Impact factor: 2.339

10.  Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers.

Authors:  G De Vriese; J Bonte
Journal:  Eur J Gynaecol Oncol       Date:  1993       Impact factor: 0.196

View more
  7 in total

Review 1.  Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Authors:  Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Oncologist       Date:  2015-02-11

2.  Prognostic factors of oncologic outcomes after fertility-preservative management with progestin in early-stage of endometrial cancer.

Authors:  Hyun Jin Roh; Hyung Joon Yoon; Dae Hoon Jeong; Tae Hwa Lee; Byung Su Kwon; Dong Soo Suh; Ki Hyung Kim
Journal:  J Res Med Sci       Date:  2021-07-31       Impact factor: 1.852

Review 3.  Should Endometrial Cancer Treatment Be Centralized?

Authors:  Vincenzo Dario Mandato; Andrea Palicelli; Federica Torricelli; Valentina Mastrofilippo; Chiara Leone; Vittoria Dicarlo; Alessandro Tafuni; Giacomo Santandrea; Gianluca Annunziata; Matteo Generali; Debora Pirillo; Gino Ciarlini; Lorenzo Aguzzoli
Journal:  Biology (Basel)       Date:  2022-05-18

4.  Medical and psychosocial aspects of fertility after cancer.

Authors:  Christine Duffy; Susan Allen
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360

Review 5.  Preserving fertility in young patients with endometrial cancer: current perspectives.

Authors:  Eleftheria Kalogera; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Int J Womens Health       Date:  2014-07-29

Review 6.  Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature.

Authors:  Sonsoles Alonso; Teresa Castellanos; Fernando Lapuente; Luis Chiva
Journal:  Ecancermedicalscience       Date:  2015-02-03

7.  Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy.

Authors:  Junyu Chen; Dongyan Cao; Jiaxin Yang; Mei Yu; Huimei Zhou; Ninghai Cheng; Jinhui Wang; Ying Zhang; Peng Peng; Keng Shen
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.